This document is an excerpt from the EUR-Lex website
Document 62015TN0041
Case T-41/15: Action brought on 23 January 2015 — Novartis v OHIM — Mabxience (HERTIXAN)
Case T-41/15: Action brought on 23 January 2015 — Novartis v OHIM — Mabxience (HERTIXAN)
Case T-41/15: Action brought on 23 January 2015 — Novartis v OHIM — Mabxience (HERTIXAN)
IO C 107, 30.3.2015, pp. 32–33
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
30.3.2015 |
EN |
Official Journal of the European Union |
C 107/32 |
Action brought on 23 January 2015 — Novartis v OHIM — Mabxience (HERTIXAN)
(Case T-41/15)
(2015/C 107/42)
Language in which the application was lodged: English
Parties
Applicant: Novartis AG (Basel, Switzerland) (represented by: M. Douglas, lawyer)
Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM)
Other party to the proceedings before the Board of Appeal: Mabxience SA (Montevideo, Uruguay)
Details of the proceedings before OHIM
Applicant: Other party to the proceedings before the Board of Appeal
Trade mark at issue: Community word mark ‘HERTIXAN’ — Application for registration No 10 660 835
Procedure before OHIM: Opposition proceedings
Contested decision: Decision of the First Board of Appeal of OHIM of 31 October 2014 in Case R 2550/2013-1
Form of order sought
The applicant claims that the Court should:
|
— |
annul the contested decision; |
|
— |
order OHIM to pay the costs. |
Plea(s) in law
|
— |
Infringement of Article 8(1)(b) of Regulation No 207/2009; |
|
— |
Infringement of Article 42(2) and (3) of Regulation No 207/2009; |
|
— |
Infringement of Article 75 of Regulation No 207/2009. |